Torc Investments and Research Reiterates "Buy" Rating on Generex Biotechnology Corporation and $3.00-$3.50 12-Month Price Target

Published: Mar 20, 2007

TORONTO -- (MARKET WIRE) -- March 20, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Torc Investments and Research LLC, a NASD registered broker-dealer, reiterated its Buy rating and a 12-month price target of $3-$3.50.

Back to news